For a company that expends so much effort presenting itself as a voice for health-care reform, McKinsey has remained silent on some of the most important health issues of our time. It did not lead the fight against cigarettes, vaping, and opioid abuse. (It had clients in all three sectors.) McKinsey did not speak out forcefully against the high cost of drugs or the tsunami of direct-to-consumer drug company advertisements. (Five drug company clients were called before Congress to defend price hikes and executive compensation.) Nor has the firm publicly raised alarms about the consolidation of
...more
